RxDoctor Payments Data

Molly Fragiacomo, APRN

Psychiatric/Mental Health · Lakeland, FLNPI 1952185258

Payments from drug & device makers

$3,088in general payments, 2019–2025

Across 172 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$594
  • AbbVie$560
  • Tris Pharma Inc$359
  • Teva Pharmaceuticals USA, Inc.$339
  • Corium, LLC$261
  • Takeda Pharmaceuticals U.S.A., Inc.$224
  • plus $750 from 12 others

What the payments were for

  • Food & beverage$3,076100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,088 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$9,156
Medicare patients
21
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl54$79,843
AristadaAripiprazole Lauroxil12$35,369
CaplytaLumateperone Tosylate15$26,919
TrintellixVortioxetine Hydrobromide18$9,837
Lurasidone Hcl25$8,252
BelsomraSuvorexant15$5,756
Aripiprazole136$5,503
Venlafaxine Hcl ErVenlafaxine Hcl143$4,710
QelbreeViloxazine Hcl11$3,998
Trazodone Hcl211$3,021
Hydroxyzine Hcl142$2,561
Methylphenidate Hcl36$2,503
Oxcarbazepine32$1,702
Bupropion XlBupropion Hcl129$1,618
Clonazepam179$1,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$560$79,84354 claims
Alkermes, Inc.Aristada$35$35,36912 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$213$26,91915 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$224$9,83718 claims
Supernus Pharmaceuticals, Inc.Qelbree$46$3,99811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →